A review of the cost of cardiovascular disease

Tarride, Jean‐Éric; Lim, Morgan; DesMeules, Marie; Luo, Wei; Burke, Natasha; O’Reilly, Daria; Bowen, James M.; Goeree, Ron

doi:10.1016/s0828-282x(09)70098-4

Cited by 197 publications

(136 citation statements)

References 31 publications

(55 reference statements)

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…• Exclusion criteria x Is a conference abstract, comment, letter to the editor, review article without original data, or grey literature or report x Provides a cost-effectiveness or cost-utility analysis of pca management x Provides a cost estimate of pca screening Cost-effectiveness and cost-utility studies were excluded because they compare health benefits and costs for treatment alternatives while reporting marginal cost, which is a focus different from that in cost-of-treatment studies reporting the absolute cost of treatments [11][12][13][14][15] .…”

Section: Literature Search and Article Selectionmentioning

confidence: 99%

“…First, the reported mean pca treatment costs were converted to Canadian dollars in the study period by using purchasing power parity for the year of cost valuation; the Canadian health care services price index was then used to convert the result into 2011 Canadian dollars [18][19][20] . An assumption for the year of costing was made for studies that did not state the year 15 . This standardization of direct costs is consistent with recommended guidelines 16,21 and similar studies in the literature 15,17,22,23 .…”

Section: Standardization Of Direct Costmentioning

confidence: 99%

See 1 more Smart Citation

Direct Cost for Initial Management of Prostate Cancer: A Systematic Review

et al. 2013

View full text Add to dashboard Cite

Background: Prostate cancer (pca) is the most common non-skin cancer among men in Canada and other Western countries. Increased prevalence and higher cost of newer treatments have led to a significant rise in the economic burden of pca. The objectives of the present study were to systematically review the literature on direct costs for the initial management of pca, and to examine the methodologic considerations across studies. Methods: Bibliographic databases were systematically searched for peer-reviewed articles in English. Studies were reviewed for methodologic considerations and mean direct cost of active surveillance or watchful waiting (as/ww) and initial treatments. Direct cost was standardized to 2011 Canadian dollars. Results: After a review of abstracts and full-text papers, seventeen articles met the eligibility criteria and were included in the review. Studies were published during 1992–2010. The studies reported on health care systems in the United States, France, the United Kingdom, German, Italy, and Spain. Our review identified a lack of methodologic consensus, leading to variation in direct costs between studies. Nevertheless, results indicate a significant direct cost of pca treatments. Conclusions: The existing literature lacks methodologically rigorous studies on the direct costs of pca treatments specific to publicly funded health care systems. Additional studies are required to appreciate the direct costs of newer treatments and the impact of their adoption on the growing economic burden of pca management.

show abstract

Section: Literature Search and Article Selectionmentioning

confidence: 99%

Section: Standardization Of Direct Costmentioning

confidence: 99%

Direct Cost for Initial Management of Prostate Cancer: A Systematic Review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…A person is defined to be hypertensive when blood pressure is 140 mm Hg systolic, or exceeds this value, and/or when it is 90 mm Hg diastolic or higher 13, 14. Most people having their first stroke have a blood pressure higher than 140/90 mm Hg 13.…”

Section: Contributing Pathologies Within the Cvd Spectrummentioning

confidence: 99%

Cannabinoids, the Heart of the Matter

Alfulaij

Meiners

Michalek

et al. 2018

JAHA

View full text Add to dashboard Cite

“…CVD also represents a major economic burden on health care systems in terms of direct (e.g., hospitalizations, rehabilitation services, physician visits, drugs) and indirect costs associated with mortality and morbidity (e.g., losses of productivity due to premature mortality and short-or long-term disability) [8,9].…”

Section: Introductionmentioning

confidence: 99%